What one share of Immunome holds
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients.
Immunome’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$2.49 |
| Capex (buildings and equipment) | $0.10 |
| Free cash flow | −$2.14 |
| Cash and investments | $1.92 |
| Book value | $4.63 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$9.55 | $0.21 | −$8.99 | — | −$32.41 |
| 2020 | — | −$5.26 | $0.17 | −$3.75 | — | — |
| 2021 | — | −$2.14 | $0.01 | −$1.59 | — | $3.98 |
| 2022 | — | −$3.09 | $0.02 | −$2.39 | — | $1.37 |
| 2023 | $0.71 | −$5.38 | $0.04 | −$0.42 | — | — |
| 2024 | $0.15 | −$5.00 | $0.12 | −$2.01 | — | $2.81 |
| 2025 | $0.08 | −$2.43 | $0.11 | −$2.30 | — | $5.61 |
Common questions about Immunome
How much does one share of Immunome earn?
Over the last 12 months, Immunome lost $2.49 for each share.
Does Immunome pay a dividend?
Immunome didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Immunome’s book value per share?
Immunome’s book value is $4.63 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Immunome have?
Each share of Immunome has $1.92 of cash and investments, as of June 30, 2026.
What is Immunome’s free cash flow per share?
−$2.14 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Immunome bought back shares?
Immunome’s share count rose about 7885% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.